Can I Take N-Acetylcysteine (NAC) with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and How Does It Work?

MK-677 is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) release from the pituitary. Unlike injectable GH, it works by mimicking ghrelin at the GH secretagogue receptor (GHS-R1a), which drives the pituitary to release endogenous GH. The resulting rise in GH then triggers hepatic IGF-1 production.

GH and IGF-1 Elevation

In a randomized, double-blind, placebo-controlled trial by Nass et al. (N=65 adults with GH deficiency), 25 mg/day of MK-677 for 12 months raised mean IGF-1 levels by 84% from baseline, compared with 2% in the placebo group 1. A separate Copinschi et al. Study in healthy older adults found a 40% IGF-1 increase at the 10 mg dose 2.

Metabolic Side Effects

Elevated GH and IGF-1 carry a metabolic cost. MK-677 consistently raises fasting blood glucose and reduces insulin sensitivity across trials. In the Nass et al. 12-month study, fasting glucose rose by a mean of 0.3 mmol/L and insulin resistance worsened on HOMA-IR 1. This is the most clinically relevant concern for anyone pairing MK-677 with a supplement that itself affects glucose metabolism.

Regulatory Status

The FDA has not approved MK-677 for any indication 3. The compound appears in research pipelines under the sponsor name Ibutamoren and remains Schedule-unclassified in the United States, but it is banned by WADA for athletic competition.

What Is NAC and What Does It Do Biochemically?

N-acetylcysteine is a pharmaceutical-grade precursor to L-cysteine, the rate-limiting amino acid in glutathione synthesis. Oral and intravenous NAC are used clinically for acetaminophen overdose, mucolytic therapy in cystic fibrosis, and as an investigational antioxidant in a range of oxidative-stress conditions.

Glutathione Precursor Role

After oral ingestion, NAC is deacetylated to cysteine in the gut and liver. Cysteine then combines with glutamate and glycine to form glutathione (GSH) via glutamate-cysteine ligase 4. Raising intracellular GSH reduces reactive oxygen species (ROS) and blunts NF-kB-mediated inflammatory signaling. This antioxidant pathway is the primary reason some researchers hypothesize NAC could offset MK-677-induced oxidative stress.

NAC and Insulin Sensitivity

Multiple human trials show NAC independently improves markers of insulin resistance. A randomized trial by Haber et al. (N=33 women with polycystic ovary syndrome) found oral NAC 1,800 mg/day for 24 weeks significantly reduced fasting insulin (P<0.05) and improved the insulin sensitivity index compared with placebo 5. A second RCT in type 2 diabetic patients found 600 mg/day for 8 weeks improved HOMA-IR 6.

NAC and GH Axis

NAC does not appear to directly stimulate or suppress GH secretion. No published human RCT has measured GH or IGF-1 as a primary endpoint following NAC supplementation alone. One rodent study observed that NAC attenuated GH-induced JAK2/STAT5 signaling under conditions of oxidative stress, but this has not been replicated in humans 7.

Does NAC Interact With MK-677 Pharmacokinetically?

Pharmacokinetic (PK) interaction occurs when one compound alters the absorption, distribution, metabolism, or excretion of another. No published human PK study has co-administered NAC and MK-677.

CYP450 Profile

MK-677 is primarily metabolized by cytochrome P450 3A4 (CYP3A4) 8. NAC is not a clinically meaningful inhibitor or inducer of CYP3A4 at standard oral doses. The Natural Medicines database rates this combination as having insufficient evidence to classify a PK interaction. Based on available mechanistic data, a significant alteration of MK-677 plasma levels by NAC is unlikely at doses used in research.

Protein Binding

MK-677 is approximately 97% plasma protein-bound. NAC at therapeutic concentrations does not competitively displace highly protein-bound drugs to a clinically significant degree 9. Displacement interactions typically require both compounds to share the same binding site at overlapping concentrations. No such overlap has been demonstrated here.

Absorption Timing

NAC can transiently lower gastric pH and increase mucosal permeability when taken in high doses. As a precaution, separating MK-677 and NAC by at least 30 to 60 minutes reduces any theoretical absorption interference, though this has not been studied directly.

Does NAC Interact With MK-677 Pharmacodynamically?

Pharmacodynamic (PD) interaction occurs when two compounds affect the same biological target or pathway, either additively or antagonistically. This is where the more substantive clinical questions arise.

Oxidative Stress Pathway

MK-677-driven GH excess generates reactive oxygen species as a downstream consequence of elevated IGF-1 signaling. High IGF-1 increases mitochondrial electron transport chain activity, which can increase superoxide production 10. NAC raises intracellular glutathione and scavenges superoxide directly. The theoretical effect is partially antagonistic to GH-induced ROS, which some researchers frame as beneficial co-administration rather than a harmful interaction.

Insulin Resistance: Opposing Effects

This is the most clinically meaningful PD consideration. MK-677 worsens insulin sensitivity; NAC improves it. These effects are additive in opposite directions rather than synergistic. A patient already prone to impaired fasting glucose who starts MK-677 may find that concurrent NAC at 1,200 to 1,800 mg/day partially attenuates the glucose rise, though no randomized trial has tested this combination directly 5 6.

The HealthRX clinical team uses the following framework when evaluating stacks that combine a GH secretagogue with an antioxidant/insulin sensitizer:

Step 1. Establish baseline fasting glucose, HbA1c, and IGF-1 before starting either compound. Step 2. Start MK-677 alone at the lowest research dose (10 mg/day) for 4 weeks and recheck fasting glucose. Step 3. If fasting glucose rises above 100 mg/dL (5.6 mmol/L) from a normal baseline, consider adding NAC 600 mg twice daily with meals. Step 4. Recheck fasting glucose, HOMA-IR, and IGF-1 at 8 weeks from NAC addition. Step 5. If glucose remains elevated at 8 weeks despite NAC, discontinue MK-677 and consult an endocrinologist.

IGF-1 and Cellular Proliferation Risk

Chronically elevated IGF-1 is associated with increased colon, breast, and prostate cancer risk in observational data 11. NAC has been studied as a chemopreventive agent in colorectal adenoma trials with mixed results 12. Whether NAC meaningfully offsets the proliferative signaling from MK-677-induced IGF-1 elevation is not established. This combination should not be positioned as a cancer-risk mitigation strategy.

Water Retention and Blood Pressure

MK-677 causes dose-dependent fluid retention, appearing in up to 18% of users in the Nass et al. Trial 1. NAC at standard doses has no meaningful effect on fluid balance or blood pressure. No additive fluid-retention risk is expected from this combination.

Clinical Evidence on NAC Safety and Dosing

NAC has a well-characterized safety profile from decades of clinical use as a pharmaceutical agent.

Oral Dosing in Published Trials

Across published RCTs, oral NAC doses range from 600 mg/day for mucolytic applications to 3,000 mg/day in acetaminophen-overdose protocols 13. The most common dose in metabolic and antioxidant trials is 600 to 1,200 mg/day in divided doses taken with food. GI side effects (nausea, diarrhea) are the principal adverse events, occurring in roughly 10 to 15% of users at doses above 1,800 mg/day.

Intravenous NAC

IV NAC used in hospital settings for acetaminophen toxicity reaches plasma concentrations far above those achievable with oral supplementation. The interaction considerations in this article apply to oral supplementation only. IV NAC protocols are governed by separate clinical guidelines from the FDA-approved prescribing information 14.

Contraindications for NAC

NAC is contraindicated in individuals with known hypersensitivity to the compound. Anaphylactoid reactions, though rare, have been reported with IV NAC at estimated incidence rates of 0.3 to 2% 15. Oral NAC carries a much lower anaphylactoid risk. People with asthma should use NAC with caution, as bronchospasm has been reported.

Clinical Evidence on MK-677 Safety

Key Trial Data

The largest published human MK-677 trial (Nass et al., N=65, 12 months) found the most common adverse events were increased appetite (52%), peripheral edema (18%), muscle pain (6%), and fasting hyperglycemia 1. A two-year extension of a separate trial in hip-fracture patients found MK-677 associated with an increased rate of congestive heart failure hospitalizations compared with placebo 16.

Long-Term IGF-1 Safety Concerns

The Endocrine Society clinical practice guideline on adult GH deficiency states: "IGF-1 should be maintained within the age- and sex-adjusted reference range during GH therapy to minimize side effects, including neoplasia risk" 17. While this guideline addresses FDA-approved GH replacement, the IGF-1 safety principle applies by extension to any compound that raises IGF-1, including MK-677.

Cortisol Effects

MK-677 transiently raises cortisol in some users. A 14-day crossover study (N=8 healthy men) found a statistically significant rise in 24-hour urinary cortisol at the 25 mg dose 2. NAC has no known effect on cortisol secretion at standard oral doses, so no additive adrenal stimulation is expected.

Who Should Not Combine NAC and MK-677?

Several populations face higher risk from either compound or the combination.

Active Malignancy or High IGF-1 at Baseline

People with a personal or first-degree family history of IGF-1-sensitive cancers (colon, breast, prostate) should avoid MK-677 entirely. Adding NAC does not make MK-677 safe in these populations 11.

Pre-Diabetes or Type 2 Diabetes

MK-677 consistently raises fasting glucose. The American Diabetes Association 2024 Standards of Care define pre-diabetes as fasting glucose 100 to 125 mg/dL 18. Adding MK-677 to a person in this range risks progression to overt hyperglycemia. While NAC may partially offset this, it is not a reliable protective agent and should not be used to justify MK-677 use in at-risk individuals.

Pediatric Populations

MK-677 is contraindicated in open-growth-plate individuals. Age <18 use is not supported by any clinical evidence and carries significant theoretical risk of acromegalic complications 3.

Pregnancy and Lactation

Neither MK-677 nor NAC supplementation (beyond standard dietary intake) has adequate safety data in pregnancy. The FDA has not evaluated MK-677 for use during pregnancy. Women who are pregnant or breastfeeding should avoid MK-677 entirely 3.

Monitoring Recommendations If You Are Already Taking Both

If you are currently using MK-677 and NAC together, stop and consult a physician. If a physician supervises continued use, the following labs are reasonable:

Baseline Panel (Before or at Start)

• Fasting glucose and insulin (to calculate HOMA-IR)
• HbA1c
• IGF-1 (age- and sex-referenced)
• Liver function tests (ALT, AST, GGT)
• Basic metabolic panel (BMP) including creatinine
• Lipid panel (GH excess can raise LDL)

Follow-Up Panel (8 to 12 Weeks)

Repeat fasting glucose, HbA1c, and IGF-1. If IGF-1 exceeds the upper limit of the age-adjusted reference range (generally above 250 to 300 ng/mL in adults aged 20 to 40) 17, reduce the MK-677 dose or discontinue. If fasting glucose exceeds 126 mg/dL on two separate occasions, discontinue MK-677 immediately and follow up with a primary care physician or endocrinologist 18.

Quarterly Monitoring for Ongoing Use

Any physician choosing to supervise ongoing MK-677 use should follow the Endocrine Society GH safety monitoring principles: IGF-1 checked every 3 months until stable, fasting glucose every 3 months, and annual assessment of cardiovascular risk factors 17.

Drug Interaction Database Ratings

The Natural Medicines database (Therapeutic Research Center) does not list a documented interaction between NAC and MK-677, reflecting the absence of direct human co-administration studies rather than confirmed safety. Absence of a listed interaction is not the same as confirmed safety. The Mayo Clinic Proceedings editorial framework for evaluating unclassified supplement-drug combinations recommends applying mechanistic plausibility analysis when direct evidence is lacking 19, which is the approach taken throughout this article.

What to Do If You Experience Side Effects While Combining Both

Elevated Fasting Glucose

Stop MK-677. Continue NAC if tolerated. Recheck fasting glucose in 2 weeks. If it does not normalize to below 100 mg/dL, consult an endocrinologist 18.

GI Distress

NAC at doses above 1,200 mg/day causes nausea and loose stools in a meaningful minority of users 13. Reduce the NAC dose to 600 mg once daily with a meal. MK-677 taken at bedtime (a common research protocol used to align its GH pulse with physiologic nocturnal GH secretion) may reduce GI overlap with morning NAC dosing.

Peripheral Edema

Edema is attributable to MK-677, not NAC. Reduce MK-677 dose from 25 mg to 10 mg/day. If edema persists, stop MK-677 and rule out cardiac or renal causes with a physician 1.